The association between conventional antidepressants and the metabolic syndrome: a review of the evidence and clinical implications - PubMed (original) (raw)

Review

doi: 10.2165/11533280-000000000-00000.

Ka Young Park, Candy W Y Law, Farah Sultan, Amanda Adams, Maria Teresa Lourenco, Aaron K S Lo, Joanna K Soczynska, Hanna Woldeyohannes, Mohammad Alsuwaidan, Jinju Yoon, Sidney H Kennedy

Affiliations

Review

The association between conventional antidepressants and the metabolic syndrome: a review of the evidence and clinical implications

Roger S McIntyre et al. CNS Drugs. 2010 Sep.

Abstract

Major depressive disorder is a prevalent recurrent medical syndrome associated with inter-episodic dysfunction. The metabolic syndrome is comprised of several established risk factors for cardiovascular disease (i.e. abdominal obesity, dyslipidaemia, dysglycaemia and hypertension). The criterion items of the metabolic syndrome collectively represent a multi-dimensional risk factor for cardiovascular disease and type 2 diabetes mellitus. Extant evidence indicates that both major depressive disorder and the metabolic syndrome, albeit distinct, often co-occur and are possibly subserved by overlapping pathophysiology and causative mechanisms. Conventional antidepressants exert variable effects on constituent elements of the metabolic syndrome, inviting the need for careful consideration prior to treatment selection and sequencing. Initiating and maintaining antidepressant therapy should include routine surveillance for clinical and/or biochemical evidence suggestive of the metabolic syndrome.

PubMed Disclaimer

Similar articles

Cited by

References

    1. J Clin Psychopharmacol. 1986 Feb;6(1):27-32 - PubMed
    1. Psychiatry Res. 1988 Dec;26(3):265-71 - PubMed
    1. Circulation. 2002 Dec 17;106(25):3143-421 - PubMed
    1. Br J Psychiatry. 1973 Nov;123(576):501-7 - PubMed
    1. Am J Psychiatry. 1991 Apr;148(4):512-6 - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources